Publications by authors named "L Perchenet"
Background: This analysis examined the effects of the activin signaling inhibitor, sotatercept, in pulmonary arterial hypertension (PAH) subgroups stratified by baseline cardiac index (CI).
Methods: Pooled data from PULSAR (N = 106; NCT03496207) and STELLAR (N = 323; NCT04576988) were analyzed using 2 different CI thresholds, <2.0 and ≥2.
Background: Pulmonary arterial hypertension (PAH) is a life-threatening, progressive disease often diagnosed late in its course.
Objectives: To present patient-reported data that were captured within a large, multinational, point-in-time survey of PAH-treating physicians and their patients to better understand the diagnostic journey.
Design: Cross-sectional survey conducted in five European countries (EU5), Japan and the USA.
Article Synopsis
- The DETECT algorithm is used to screen for pulmonary arterial hypertension (PAH) in patients with systemic sclerosis (SSc) using noninvasive data and guiding referrals for further testing.
- A recent analysis showed that the performance of DETECT in identifying PAH risk using the updated 2022 ESC/ERS definitions was slightly less sensitive (88.2%) compared to the previous 2014 definitions (95.8%), but its specificity improved.
- Despite the changes in PAH definitions, DETECT remains a valid tool for screening PAH in SSc patients, confirming its ongoing relevance in clinical practice.
The main aim of this analysis was to investigate time from symptom onset (chronic unexplained dyspnoea [CUD]) to diagnosis of Group 1 pulmonary hypertension (PH)-pulmonary arterial hypertension (PAH)-and to characterize healthcare resource utilization leading up to diagnosis using a nationwide US claims and an electronic health record (EHR) database from Optum. Eligible patients were ≥18 years old at first CUD diagnosis (index event) and had a PAH diagnosis on or after index date. Based on administrative codes, PAH was defined as right heart catheterization (RHC), ≥ 2 PAH diagnoses (1 within a year of RHC), and ≥1 post-RHC prescription for PAH treatment.
View Article and Find Full Text PDF